Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
No. 4 Pixu decoction is an investigational Traditional Chinese Medicine (TCM) herbal formulation developed by Xiyuan Hospital of the China Academy of Chinese Medical Sciences. It is designed for the treatment of functional diarrhea, specifically targeting the Liver Depression and Spleen Deficiency (Ganyu Pixu) syndrome as identified through TCM differential diagnosis. The decoction is part of a standardized series of formulas used in clinical trials to evaluate the efficacy of syndrome-based treatment in patients meeting the Rome III criteria for functional diarrhea. Its therapeutic goal is to regulate the Liver and strengthen the Spleen, thereby addressing the underlying disharmony that leads to gastrointestinal symptoms such as abdominal pain and frequent loose stools. In clinical studies, it is typically administered as a standardized mixture of herbal granules.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on No. 4 Pixu decoction.